Ensysce Biosciences, Inc.

NasdaqCM:ENSC Rapport sur les actions

Capitalisation boursière : US$9.0m

Ensysce Biosciences Gestion

Gestion contrôle des critères 4/4

Ensysce Biosciences' CEO is D. Kirkpatrick, appointed in Jan 2009, has a tenure of 15.83 years. total yearly compensation is $508.58K, comprised of 79.6% salary and 20.4% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $1.03K. The average tenure of the management team and the board of directors is 4.9 years and 4.3 years respectively.

Informations clés

D. Kirkpatrick

Directeur général

US$508.6k

Rémunération totale

Pourcentage du salaire du PDG79.6%
Durée du mandat du directeur général15.8yrs
Propriété du PDG0.01%
Durée moyenne d'occupation des postes de direction4.9yrs
Durée moyenne du mandat des membres du conseil d'administration4.3yrs

Mises à jour récentes de la gestion

Recent updates

Ensysce Biosciences secures $8M convertible note financing

Jul 01

Analyse de la rémunération des PDG

Comment la rémunération de D. Kirkpatrick a-t-elle évolué par rapport aux bénéfices de Ensysce Biosciences?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$11m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023US$509kUS$405k

-US$11m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$20m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$623kUS$393k

-US$25m

Sep 30 2022n/an/a

-US$30m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$288kUS$174k

-US$30m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$99k

Mar 31 2021n/an/a

US$172k

Dec 31 2020US$156kUS$156k

US$57k

Rémunération vs marché: D.'s total compensation ($USD508.58K) is about average for companies of similar size in the US market ($USD655.65K).

Rémunération et revenus: D.'s compensation has been consistent with company performance over the past year.

PDG

D. Kirkpatrick (67 yo)

15.8yrs

Titularisation

US$508,575

Compensation

Dr. D. Lynn Kirkpatrick, Ph.D. is a Co Founder of ProlX Pharmaceuticals Corporation and has been its Chief Executive Officer since 1999. She has been Chief Executive Officer of Ensysce Biosciences, Inc. si...

Équipe de direction

NomPositionTitularisationCompensationPropriété
D. Kirkpatrick
President15.8yrsUS$508.58k0.011%
$ 1.0k
David Humphrey
CFO, Secretary & Treasurer3.8yrsUS$441.95k0.0015%
$ 135.2
Geoffrey Birkett
Chief Commercial Officer6.1yrsUS$392.35k0%
$ 0
Jeffrey Millard
Chief Operating Officer1.1yrspas de donnéespas de données
William Schmidt
Chairman of Clinical Advisory Board & Chief Medical Officer8.8yrspas de donnéespas de données
Linda Pestano
Chief Development Officer3.1yrspas de données0%
$ 0

4.9yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: ENSC's management team is considered experienced (4.9 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
D. Kirkpatrick
President7.5yrsUS$508.58k0.011%
$ 1.0k
William Schmidt
Chairman of Clinical Advisory Board & Chief Medical Officer2.2yrspas de donnéespas de données
Robert Gower
Independent Chairman of the Board16.8yrsUS$47.60k0.88%
$ 79.2k
Lee Rauch
Independent Director2.8yrsUS$29.17k0%
$ 0
Andrew Benton
Independent Director4.9yrsUS$30.10k0.14%
$ 13.0k
Richard Dart
Member of the Clinical Advisory Boardno datapas de donnéespas de données
Steven Martin
Independent Director4.3yrsUS$32.92k0%
$ 0
Lynn Webster
Member of the Clinical Advisory Boardno datapas de donnéespas de données
Hui-Chung Chang
Independent Director8.8yrsUS$30.10k0.23%
$ 20.3k
Jeffrey Gudin
Member of the Clinical Advisory Boardno datapas de donnéespas de données
Curtis Rosebraugh
Independent Director3.4yrsUS$25.42k0%
$ 0
Adam Levin
Independent Director3.4yrsUS$27.92k0%
$ 0

4.3yrs

Durée moyenne de l'emploi

67.5yo

Âge moyen

Conseil d'administration expérimenté: ENSC's board of directors are considered experienced (4.3 years average tenure).